🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. Combination Treatment of PDS0101 and Pembrolizumab

    PDS Biotechnology Corp

    Recurrent Head and Neck Cancer

    phase 3 other active

    1 trial

  2. Combipress 150 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 150 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/10 mg επικαλυμμένα με λεπτό υμένιο δισκία, Combipress 300 mg/5 mg επικαλυμμένα με λεπτό υμένιο δισκία

    Lacuna Pharma Pty Ltd

    Arterial Hypertension

    phase 3 small molecule active

    1 trial

  3. Commercially available 0,9 % sterile saline solution with marketing authorization will be utilized as the placebo., KEYTRUDA 25 mg/mL concentrate for solution for infusion, INBRX-106, INBRX-106

    Inhibrx Biosciences

    Head and Neck Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  4. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  5. Concizumab C 100 mg/mL PDS290, Concizumab C 40 mg/mL PDS290, Concizumab C 10 mg/mL PDS290

    NovoThirteen

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  6. Concizumab C 40 mg/mL PDS290, Concizumab C 100 mg/mL PDS290

    NovoThirteen

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  7. Conjunctival Provocation Test Grass-Mix LETI 30 HEP/ml, Conjunctival Provocation Test Olea europaea LETI 30 HEP/ml, Depigoid DUO Grass-Mix/Olea (1000 DPP/ml + 1000 DPP/ml), PLACEBO (Depigoid): the placebo is the solvent used in the investigational medicinal products’ (IMP) formulation. The resulting product is a suspension.

    Lacuna Pharma Pty Ltd

    Allergic rhinoconjunctivitis with or without asthma due to clinically relevant sensitisation to grass and olive pollen.

    phase 3 small molecule active

    1 trial

  8. Copiktra 25 mg hard capsules, Copiktra 15 mg hard capsules, DUVELISIB , BENDAMUSTINE , GEMCITABINE

    Secura Bio Limited

    relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype, relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype

    phase 3 small molecule active

    1 trial

  9. Crovalimab, ECULIZUMAB, Crovalimab

    Hoffmann-La Roche

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  10. Cx601

    Takeda

    Crohn's Disease

    phase 3 other completed

    3 trials

  11. Cyclophosphamide Injection 500 mg., Vincristine Sulfate 1 mg/ml solution for injection, Cisplatin 1 mg/ml concentrate for solution for infusion, Temodal 100 mg hard capsules, Etoposide 20 mg/ml Concentrate for Solution for Infusion, Thiotepa 15 mg Powder for solution for injection , Qarziba 4.5 mg/mL concentrate for solution for infusion, Melphalan 50 mg concentrate and solvent for solution for injection/infusion, Busulfan 6 mg/ml concentrate for solution for infusion, CARBOPLATINE MEDAC 10 mg/mL, solution

    The George Institute

    Patients with High Risk Neuroblastoma

    phase 3 small molecule active

    1 trial

  12. DACARBAZINE, IPILIMUMAB, IDE196 (LXS196), NIVOLUMAB, CRIZOTINIB, CRIZOTINIB, PEMBROLIZUMAB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  13. DACARBAZINE, PEMBROLIZUMAB, IDE196 (LXS196), CRIZOTINIB, IPILIMUMAB, NIVOLUMAB, CRIZOTINIB, IDE196 (LXS196)

    IDEAYA Biosciences

    HLA-A2 negative metastatic uveal melanoma

    phase 3 small molecule active

    1 trial

  14. DAPAGLIFLOZIN, PLACEBO

    Disc Medicine

    Hypomagnesemia due to HNF1beta mutation

    phase 3 small molecule active

    1 trial

  15. DAPAGLIFLOZIN, PLACEBO DE DAPAGLIFLOZIN 10 mg

    Pari Pharma GmbH

    Cardiac failure

    phase 3 small molecule active

    1 trial

  16. DAPAGLIFLOZIN, Placebo for dapagliflozin film-coated tablets 10 mg

    Disc Medicine

    Combined endpoint of all-cause mortality, kidney failure, and hospitalization for heart failure in the overall study population

    phase 3 small molecule active

    1 trial

  17. DAPAGLIFLOZIN, Zibotentan + Dapagliflozin, Zibotentan + Dapagliflozin

    AstraZeneca AB

    Chronic Kidney Disease and High Proteinuria

    phase 3 small molecule active

    1 trial

  18. DARAXONRASIB (RMC-6236), DOCETAXEL, DARAXONRASIB (RMC-6236)

    Revolution Medicines

    non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  19. DASATINIB, IMATINIB, BOSUTINIB, DASATINIB, NILOTINIB, BOSUTINIB, DASATINIB, DASATINIB, NILOTINIB, DASATINIB, IMATINIB, IMATINIB, DASATINIB, ASCIMINIB HYDROCHLORIDE

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  20. DAUNORUBICIN HYDROCHLORIDE, FLUDARABINE, MYLOTARG 5 mg powder for concentrate for solution for infusion, CYCLOPHOSPHAMIDE, TREOSULFAN, CYTARABINE, BUSULFAN

    Fondazione Telethon ETS

    Favorable-intermediate-risk Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  21. DBV712

    DBV Technologies

    Allergy, Peanut

    phase 3 small molecule active

    1 trial

  22. DCC-3014, DCC-3014, Placebo to match DCC-3014

    Lacuna Pharma Pty Ltd

    Tenosynovial Giant Cell Tumor

    phase 3 small molecule active

    1 trial

  23. DEGARELIX, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, DEGARELIX, DEGARELIX, TRIPTORELIN , DEGARELIX, LEUPRORELIN ACETATE, TRIPTORELIN

    Ningbo Cancer Hospital

    very high risk localized or locally advanced prostate cancer

    phase 3 small molecule active

    1 trial

  24. DEXAMETHASONE , DARATUMUMAB, DARZALEX 1800 mg solution for injection, LENALIDOMIDE

    Pari Pharma GmbH

    Onco-hematology

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources